{"transactions":[{"id":2044229,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":117610,"kind":"person","name":"Hagel Jillian Marie","position":1,"cik":"0001883891","reported_name":"Hagel Jillian Marie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Vice President of Innovation"}}],"security":"Common Stock","published_at":"2023-01-27T22:05:31.000Z","date":"2023-01-25","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the restricted stock units (the \"RSUs\") granted to the reporting person pursuant to the Enveric Biosciences, Inc. (the \"Company\") 2020 Long-Term Incentive Plan. For each vested restricted stock unit, the reporting person will be entitled to receive one share of common stock. The RSUs vest in four equal annual installments, with the first installment vesting upon the one year anniversary of the date of issuance."}],"balance_after":35802,"source":{"system":"sec-edgar","filing":"0001493152-23-002801","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/890821/000149315223002801/ownership.xml","form_type":"4"}},{"id":2046804,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":117610,"kind":"person","name":"Hagel Jillian Marie","position":1,"cik":"0001883891","reported_name":"Hagel Jillian Marie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Stock","published_at":"2023-01-25T21:30:31.000Z","date":"2021-10-13","kind":"grant","acquired":true,"shares":10500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"50% of the RSUs shall vest over 4 years in equal annual installments, with the first tranche to vest on September 16, 2022. 50% of the RSUs shall vest in 3 approximately equal tranches on each of December 31, 2022, 2023 and 2024, if the Company's average VWAP (calculated as the average over the fourth calendar quarter of each of 2022, 2023 and 2024, as applicable, of the daily volume weighted average price of a share of common stock), exceeds $119.00, $130.50 and $143.50, respectively."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 10,633 shares previously held through the Hagel 2020 Family Trust, which were distributed to the reporting person and are now owned directly."}],"balance_after":23802,"source":{"system":"sec-edgar","filing":"0001493152-23-002449","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/890821/000149315223002449/ownership.xml","form_type":"4"}},{"id":2046803,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":117610,"kind":"person","name":"Hagel Jillian Marie","position":1,"cik":"0001883891","reported_name":"Hagel Jillian Marie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Stock","published_at":"2023-01-25T21:30:31.000Z","date":"2021-10-13","kind":"grant","acquired":true,"shares":1021,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person received the RSUs as a one-time signing bonus upon the commencement of the reporting person's employment with the Company. 50% of the RSUs shall vest over 2 years in equal annual installments, with the first tranche to vest on September 16, 2022. 50% of the RSUs shall vest over 2 years in equal annual installments, if the Company's average VWAP exceeds 110% and 120% of $158.925, respectively."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 10,633 shares previously held through the Hagel 2020 Family Trust, which were distributed to the reporting person and are now owned directly."}],"balance_after":13302,"source":{"system":"sec-edgar","filing":"0001493152-23-002449","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/890821/000149315223002449/ownership.xml","form_type":"4"}},{"id":2540987,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":117610,"kind":"person","name":"Hagel Jillian Marie","position":1,"cik":"0001883891","reported_name":"Hagel Jillian Marie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Warrants","published_at":"2021-10-18T12:03:17.000Z","date":"2021-09-16","kind":"grant","acquired":true,"shares":1329,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the Amalgamation Agreement, following the effective time of the Amalgamation, each holder of an outstanding MagicMed warrant is entitled to receive upon exercise of such MagicMed warrant that number of Company shares which the holder would have been entitled to receive as a result of the Amalgamation if, immediately prior to the Amalgamation, such holder had exercised the MagicMed warrants."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The Reporting Person held MagicMed warrants immediately prior to the effective time of the Amalgamation to acquire 5,000 shares of common stock of MagicMed with an exercise price of $0.75 per share. At the effective time of the Amalgamation, the Reporting Person is entitled to receive shares of Company common stock upon exercise of the MagicMed warrants."}],"balance_after":1329,"derivative":{"exercise_price":2.82,"exercise_date":"2021-09-16","expiration_date":"2023-09-16","underlying":"Common Stock","underlying_shares":1329},"source":{"system":"sec-edgar","filing":"0001493152-21-025638","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/890821/000149315221025638/ownership.xml","form_type":"4"}},{"id":2540986,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":117610,"kind":"person","name":"Hagel Jillian Marie","position":1,"cik":"0001883891","reported_name":"Hagel Jillian Marie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Warrants","published_at":"2021-10-18T12:03:17.000Z","date":"2021-09-16","kind":"grant","acquired":true,"shares":531602,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the Amalgamation Agreement, following the effective time of the Amalgamation, each holder of an outstanding MagicMed warrant is entitled to receive upon exercise of such MagicMed warrant that number of Company shares which the holder would have been entitled to receive as a result of the Amalgamation if, immediately prior to the Amalgamation, such holder had exercised the MagicMed warrants."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The Reporting Person held MagicMed warrants immediately prior to the effective time of the Amalgamation to acquire 2,000,000 shares of common stock of MagicMed with an exercise price of $0.25 per share. At the effective time of the Amalgamation, the Reporting Person is entitled to receive shares of Company common stock upon exercise of the MagicMed warrants."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Held indirectly through the Hagel 2020 Family Trust, a trust benefiting (but not controlled by) Dr. Hagel and her family."}],"balance_after":531602,"derivative":{"exercise_price":0.94,"exercise_date":"2021-09-16","expiration_date":"2025-05-26","underlying":"Common Stock","underlying_shares":531602},"source":{"system":"sec-edgar","filing":"0001493152-21-025638","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/890821/000149315221025638/ownership.xml","form_type":"4"}},{"id":2540985,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":117610,"kind":"person","name":"Hagel Jillian Marie","position":1,"cik":"0001883891","reported_name":"Hagel Jillian Marie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Warrants","published_at":"2021-10-18T12:03:17.000Z","date":"2021-09-16","kind":"grant","acquired":true,"shares":79740,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the Amalgamation Agreement, following the effective time of the Amalgamation, each holder of an outstanding MagicMed warrant is entitled to receive upon exercise of such MagicMed warrant that number of Company shares which the holder would have been entitled to receive as a result of the Amalgamation if, immediately prior to the Amalgamation, such holder had exercised the MagicMed warrants."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The Reporting Person held MagicMed warrants immediately prior to the effective time of the Amalgamation to acquire 300,000 shares of common stock of MagicMed with an exercise price of $0.25 per share. At the effective time of the Amalgamation, the Reporting Person is entitled to receive shares of Company common stock upon exercise of the MagicMed warrants."}],"balance_after":79740,"derivative":{"exercise_price":0.94,"exercise_date":"2021-09-16","expiration_date":"2025-05-26","underlying":"Common Stock","underlying_shares":79740},"source":{"system":"sec-edgar","filing":"0001493152-21-025638","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/890821/000149315221025638/ownership.xml","form_type":"4"}},{"id":2540984,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":117610,"kind":"person","name":"Hagel Jillian Marie","position":1,"cik":"0001883891","reported_name":"Hagel Jillian Marie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Stock Options","published_at":"2021-10-18T12:03:17.000Z","date":"2021-09-16","kind":"grant","acquired":true,"shares":99675,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Amalgamation Agreement, following the effective time of the Amalgamation, each outstanding MagicMed stock option was converted into an option to purchase the number of Company shares equal to the Exchange Ratio multiplied by the number of MagicMed shares subject to such MagicMed stock option."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Received in exchange for options to acquire 375,000 shares of common stock of MagicMed with an exercise price of $0.50 per share in connection with the Amalgamation."}],"balance_after":99675,"derivative":{"exercise_price":1.88,"exercise_date":"2021-09-16","expiration_date":"2026-04-05","underlying":"Common Stock","underlying_shares":99675},"source":{"system":"sec-edgar","filing":"0001493152-21-025638","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/890821/000149315221025638/ownership.xml","form_type":"4"}},{"id":2540983,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":117610,"kind":"person","name":"Hagel Jillian Marie","position":1,"cik":"0001883891","reported_name":"Hagel Jillian Marie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Stock","published_at":"2021-10-18T12:03:17.000Z","date":"2021-09-16","kind":"grant","acquired":true,"shares":531602,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to an Amalgamation Agreement, dated May 24, 2021 (the \"Amalgamation Agreement\"), by and among Enveric Biosciences, Inc. (the \"Company\"), 1306432 B.C. Unlimited Liability Company (formerly known as 1306432 B.C. Ltd.), (\"HoldCo\"), 1306436 B.C. Ltd., (\"Purchaser\"), and MagicMed Industries Inc. (\"MagicMed\"), upon the completion of the Amalgamation, the shareholders of MagicMed received shares of common stock of the Company equal to the product of 0.2658 (the \"Exchange Ratio\") multiplied by the number of MagicMed shares held by each such MagicMed shareholder."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Received in exchange for 2,000,000 shares of common stock of MagicMed pursuant to the Amalgamation Agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Held indirectly through the Hagel 2020 Family Trust, a trust benefiting (but not controlled by) Dr. Hagel and her family."}],"balance_after":531602,"source":{"system":"sec-edgar","filing":"0001493152-21-025638","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/890821/000149315221025638/ownership.xml","form_type":"4"}},{"id":2540982,"issuer":{"id":8193,"kind":"organization","name":"Enveric Biosciences, Inc."},"owners":[{"id":117610,"kind":"person","name":"Hagel Jillian Marie","position":1,"cik":"0001883891","reported_name":"Hagel Jillian Marie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Common Stock","published_at":"2021-10-18T12:03:17.000Z","date":"2021-09-16","kind":"grant","acquired":true,"shares":82398,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to an Amalgamation Agreement, dated May 24, 2021 (the \"Amalgamation Agreement\"), by and among Enveric Biosciences, Inc. (the \"Company\"), 1306432 B.C. Unlimited Liability Company (formerly known as 1306432 B.C. Ltd.), (\"HoldCo\"), 1306436 B.C. Ltd., (\"Purchaser\"), and MagicMed Industries Inc. (\"MagicMed\"), upon the completion of the Amalgamation, the shareholders of MagicMed received shares of common stock of the Company equal to the product of 0.2658 (the \"Exchange Ratio\") multiplied by the number of MagicMed shares held by each such MagicMed shareholder."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Received in exchange for 310,000 shares of common stock of MagicMed pursuant to the Amalgamation Agreement."}],"balance_after":82398,"source":{"system":"sec-edgar","filing":"0001493152-21-025638","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/890821/000149315221025638/ownership.xml","form_type":"4"}}]}